【摘要】 目的探讨CT引导下放射性¹²⁵Ⅰ粒子组织间植入治疗复发直肠癌的技术可行性、疗效和副反应。方法23例直肠癌术后复发患者行CT引导下¹²⁵Ⅰ粒子植入术,其中3例行2次粒子植入。20例手术采用硬膜外麻醉,3例局部麻醉。20例腹卧位,3例仰卧位。术前通过治疗计划系统行三维治疗计划,确定粒子数目、空间分布和粒子针数目。既往放疗者肿瘤匹配周边剂量为90～120 Gy,未行放疗者为140～160 Gy。治疗PTV为CTV外加1 cm。粒子活度18．5～25．9MBq（0．5～0．7mCi）。植入粒子33～137颗,术后即刻行CT扫描进行质量验证。术后1周3例患者加三维适形放疗,2～3 Gy/次,总剂量45～50 Gy。每3个月复查1次CT。结果随访3～28个月。术后平均7 d疼痛缓解,其中完全缓解12/15,部分缓解2/15,无变化1/15,总有效率为93%。肿瘤局部控制率为87%。中位生存时间14个月,1、2年生存率分别为93%和50%。4例全身合并全身转移,2例8个月和12个月时死于肺转移。无治疗相关严重并发症发生。结论CT引导放射性¹²⁵Ⅰ粒子植入治疗复发直肠癌具有安全、微创、并发症率低和疗效肯定等优势,疗后配合外放疗和全身化疗有望进一步提高疗效。更多还原

【Abstract】 Objective To investigate the technological feasibility,efficacy and morbidity of cr guided ¹²⁵Ⅰseed implantation for recurrent rectum cancer.Methods Twenty-three patients with recurrent rectum cancer were treated with cr guided interstitial ¹²⁵Ⅰseed brachytherapy.In 20 patients the procedure was performed under epidural anesthesia and 3 patients under local anesthesia.Treatment planning system was used to calculate the number of seeds,the space distribution and the introduction of the seeding needles.Matched peripheral dose （MPD） of ¹²⁵Ⅰseed implantation ranged from 90-120 Gy for patients who had had external radiotherapy,and 140- 160Gy for those who had not.The planning target volume（PTV）was clinical target volume（CTV）plus 1 cm margin.The range of radioactivity of the ¹²⁵Ⅰseeds was 18.5-25.9 MBq.All these 23 patients had CT scan at 5 mm intervals after implantation for quality evaluation,together with routine chest,pelvic X-ray films within 24-48 hours after seed implantation.Three patients received three-dimensioual conformal radiation therapy（3DCRT） to a total dose of45-50 Gy,with 2-3 Gy/f.Follow-up time was from 3 to 28 months.Results All patients was able to tolerate seed implantation well.Complete pain relief was observed in 12/15,and partial relief in 2/15 and no response in 1/15,with a response rate of 93%.The local control rate was 87%.The 1-and 2-year survival rate was 93% and 50% respectively.Two of four patients have died of dissemination to the lung after 8 and 12 months. One seed has migrated into the pelvis without causing any untoward morbidity.Conclusion CT guided ¹²⁵Ⅰseed implantation for recurrent rectum cancer is safe,minimally invasive,causing only mild morbidity.It possesses a high efficacy,yet it should be given in combination with external beam radiation and chemotherapy,should distant metastasis be observed.更多还原